Plain-English translation of NCT06850090 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a newer chemotherapy drug called TAS-102, combined with radiation therapy, works better than the standard chemotherapy drug capecitabine when treating rectal cancer. Both groups receive radiation therapy, but they receive different chemotherapy medications alongside it. The goal is to see which combination helps more patients have a complete response to treatment before surgery.
Current standard treatment for locally advanced rectal cancer doesn't work completely for all patients—only 8% to 20% achieve a complete response. This medication is being tested because early research suggests it might help more patients achieve a complete response, which could mean better outcomes and a chance to preserve normal bowel function.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either TAS-102 or capecitabine alongside long-course radiation therapy. The radiation and chemotherapy are given together over several weeks. After this treatment period, you will undergo surgery to remove the cancer. Throughout the trial, you'll have regular doctor visits, imaging scans, and blood tests to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China